Damora Therapeutics (DMRA) Income from Continuing Operations (2019 - 2026)
Damora Therapeutics' (DMRA) quarterly Income from Continuing Operations came in at 27783000.0 in Q1 2026, down 996.84% YoY from 3097871.15 in Q1 2025, and up 85.89% on a QoQ basis from 196876000.0 in Q4 2025.
Damora Therapeutics (DMRA) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Damora Therapeutics (DMRA) has 8 years of Income from Continuing Operations data on file, last reported at 27783000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 996.84% year-over-year to 27783000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 231229000.0 (down 1150.22% YoY) and the FY2025 annual result came in at 205979000.0, down 860.77% from the prior year.
- Income from Continuing Operations advanced to 27783000.0 in Q1 2026, from 196876000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1667000.0 in Q4 2023 to a low of 196876000.0 in Q4 2025.
- A 5-year average of 20546617.24 and a median of 8136000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations surged 112.19% — and 2025, when it sank 2820.58%.
- Tracing DMRA's Income from Continuing Operations over 5 years: stood at 13680000.0 in 2022, then surged by 112.19% to 1667000.0 in 2023, then slumped by 504.38% to 6741000.0 in 2024, then slumped by 2820.58% to 196876000.0 in 2025, then soared by 85.89% to 27783000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 27783000.0 (Q1 2026), 196876000.0 (Q4 2025), and 3133000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - | -31.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -31.22 Mn |
| Mar 31, 2026 | -27.78 Mn |
| Dec 31, 2025 | -196.88 Mn |
| Sep 30, 2025 | -3.13 Mn |
| Jun 30, 2025 | -3.44 Mn |
| Mar 31, 2025 | -2.53 Mn |
| Dec 31, 2024 | -6.74 Mn |
| Sep 30, 2024 | -3.88 Mn |
| Jun 30, 2024 | -5.34 Mn |
| Mar 31, 2024 | -5.48 Mn |
| Dec 31, 2023 | 1.67 Mn |
| Sep 30, 2023 | -8.14 Mn |
| Jun 30, 2023 | -10.74 Mn |
| Mar 31, 2023 | -14.92 Mn |
| Dec 31, 2022 | -13.68 Mn |
| Sep 30, 2022 | -13.76 Mn |
| Jun 30, 2022 | -17.24 Mn |
| Mar 31, 2022 | -17.28 Mn |
| Dec 31, 2021 | -13.58 Mn |
| Sep 30, 2021 | -15.00 Mn |